Retrophin Inc. (Nasdaq; RTRX) completed the $62.5 million acquisition of Manchester Pharmaceuticals LLC.

The deal, originally announced in February, included an upfront payment of $29.5 million, plus other payments based on the sales of Manchester's products. Manchester develops Chenodal, which treats gallstones, and Vecamyl, which helps patients manage severe hypertension. Both medicines have been approved by the U.S. Food and Drug Administration (FDA).

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.